Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative neoadjuvant trial in high‐risk localized prostate cancer
Open Access
- 23 March 2021
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 81 (7) , 418-426
Abstract
Background: Localized prostate cancers (PCs) may resist neoadjuvant androgen receptor (AR)‐targeted therapies as a result of persistent intraprostatic androgens arising through upregulation of steroidogenic enzymes. Therefore, we sought to evaluate clinical effects of neoadjuvant indomethacin (Indo), which inhibits the steroidogenic enzyme AKR1C3, in addition to combinatorial anti‐androgen blockade, in men with high‐risk PC undergoing radical prostatectomy (RP).Methods: This was an open label, single‐site, Phase II neoadjuvant trial in men with high to very‐high‐risk PC, as defined by NCCN criteria. Patients received 12 weeks of apalutamide (Apa), abiraterone acetate plus prednisone (AAP), degarelix, and Indo followed by RP. Primary objective was to determine the pathologic complete response (pCR) rate. Secondary objectives included minimal residual disease (MRD) rate, defined as residual cancer burden (RCB) ≤ 0.25cm3 (tumor volume multiplied by tumor cellularity) and elucidation of molecular features of resistance.Results: Twenty patients were evaluable for the primary endpoint. Baseline median prostate‐specific antigen (PSA) was 10.1 ng/ml, 4 (20%) patients had Gleason grade group (GG) 4 disease and 16 had GG 5 disease. At RP, 1 (5%) patient had pCR and 6 (30%) had MRD. Therapy was well tolerated. Over a median follow‐up of 23.8 months, 1 of 7 (14%) men with pathologic response and 6 of 13 (46%) men without pathologic response had a PSA relapse. There was no association between prostate hormone levels or HSD3B1 genotype with pathologic response.Conclusions: In men with high‐risk PC, pCR rates remained low even with combinatorial AR‐directed therapy, although rates of MRD were higher. Ongoing follow‐up is needed to validate clinical outcomes of men who achieve MRD.Keywords
Funding Information
- Janssen Pharmaceutica
- Prostate Cancer Foundation (W81XWH‐18‐PC180686)
This publication has 33 references indexed in Scilit:
- Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II studyInvestigational New Drugs, 2014
- Targeted Androgen Pathway Suppression in Localized Prostate Cancer: A Pilot StudyJournal of Clinical Oncology, 2014
- A Gain-of-Function Mutation in DHT Synthesis in Castration-Resistant Prostate CancerCell, 2013
- Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trialThe Lancet Oncology, 2012
- Intratumoral De Novo Steroid Synthesis Activates Androgen Receptor in Castration-Resistant Prostate Cancer and Is Upregulated by Treatment with CYP17A1 InhibitorsCancer Research, 2011
- Predicting 15-Year Prostate Cancer Specific Mortality After Radical ProstatectomyJournal of Urology, 2011
- Prostate Cancer–Specific Mortality After Radical Prostatectomy for Patients Treated in the Prostate-Specific Antigen EraJournal of Clinical Oncology, 2009
- Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumor GrowthCancer Research, 2008
- An indomethacin analogue, N-(4-chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3α-HSD, type 5 17β-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone independent malignanciesBiochemical Pharmacology, 2008
- Increased Expression of Genes Converting Adrenal Androgens to Testosterone in Androgen-Independent Prostate CancerCancer Research, 2006